Physician profile

Anupama Nutakki

Internal Medicine · Mesa, AZ

NPI 1386605657

$1,122.83

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $235.93 2020-2022
Astellas Pharma US INC $152.55 2021-2022
Amgen INC. $141.39 2020-2022
Lilly USA, LLC $88.64 2020-2021
Boehringer Ingelheim Pharmaceuticals, INC. $84.26 2020-2021
Abbvie INC. $58.09 2021
Sunovion Pharmaceuticals INC. $38.89 2020
Boston Scientific Corporation $36.93 2020-2021
Biohaven Pharmaceuticals, INC. $30.83 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $29.93 2020-2022
Pfizer INC. $28.22 2020-2021
Amarin Pharma, INC. $27.16 2020-2021
Janssen Pharmaceuticals, INC $21.23 2020
Xeris Pharmaceuticals, INC. $18.26 2022
Dexcom, INC. $17.42 2022
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $17.23 2022
Merck Sharp & Dohme LLC $17.01 2020
Nevro Corp. $14.13 2021
Abbott Laboratories $14.13 2021
Hologic Sales and Service, LLC $13.83 2020
Stryker Corporation $12.86 2020
Mylan Specialty L.P. $12.80 2020
Takeda Pharmaceuticals U.S.A., INC. $11.11 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anupama Nutakki

$1,122.83

in general payments reported 2019-2025

Years
2020-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/17526/anupama-nutakki

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.